Article
Hematology
Tycel Phillips, Henry Chan, Constantine S. Tam, Alessandra Tedeschi, Patrick Johnston, Sung Yong Oh, Stephen Opat, Hyeon-Seok Eom, Heather Allewelt, Jennifer C. Stern, Ziwen Tan, William Novotny, Jane Huang, Judith Trotman
Summary: The study demonstrates favorable outcomes for patients with relapsed/refractory marginal zone lymphoma and follicular lymphoma treated with the selective Bruton's tyrosine kinase inhibitor zanubrutinib. The results support zanubrutinib as a potentially meaningful addition to available therapies for these patients.
Review
Medicine, General & Internal
Pauline Brice, Eric de Kerviler, Jonathan W. Friedberg
Summary: Classical Hodgkin lymphoma is a relatively common lymphoma that is generally considered highly curable with standard first-line chemotherapy and radiotherapy, although some patients may not be cured or may experience late toxic effects leading to premature death. Recent changes in the gold standard of chemotherapy, now often including immunotherapy in relapse settings, have further impacted treatment outcomes.
Article
Chemistry, Medicinal
Jingjing Deng, Baogeng Hou, Xiaohan Hou, Yuxin Chen, Tao Zhang, Hua Chen, Yuanze Wang, Xiaoyang Li
Summary: In this study, a series of benzamide-based PI3K/HDAC dual inhibitors were designed and synthesized, and representative compound PH14 showed potent inhibitory activity toward PI3K alpha and HDAC3, as well as the ability to promote apoptosis.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
(2023)
Review
Immunology
Zhongwang Wang, Hui Zhou, Jing Xu, Jinjin Wang, Ting Niu
Summary: This systematic review and meta-analysis evaluated the efficacy and safety of Duvelisib in different relapsed or refractory lymphoid neoplasms. The results showed that Duvelisib has favorable efficacy in treating relapsed or refractory CLL/SLL, iNHL, MCL, and AITL. Proper identification and management can mitigate the risk and severity of Duvelisib treatment.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Thomas D. Rodgers, AnnaLynn M. Williams, Andrea Baran, Patrick M. Reagan, Carla Casulo, Clive S. Zent, Andrew Evans, Jonathan W. Friedberg, Paul M. Barr
Summary: A retrospective review of 79 patients found that patients receiving novel combination therapy and previously untreated patients were more likely to develop severe adverse events. This suggests caution against the use of untested PI3K inhibitor combinations in routine practice.
LEUKEMIA & LYMPHOMA
(2021)
Article
Biology
Lei Jia, Lingling Wang, Yingmin Jiang, Lei Xu, Yanfei Cai, Yun Chen, Jian Jin, Huiyong Sun, Jingyu Zhu
Summary: Phosphatidylinositol 3-kinase (PI3K) is a central regulator of cellular functions and a potential target for treating various diseases. This study focuses on PI3K gamma, which plays an essential role in immune signaling. The development of selective inhibitors for PI3K gamma is challenging due to its high sequence homology with other isoforms. By employing various molecular modeling approaches, this study reveals the selective binding mechanisms of three inhibitors (Idelalisib/CAL-101, Duvelisib/IPI-145, and Eganelisib/IPI-549) targeting PI3K gamma. The findings provide important information for the rational design and optimization of PI3K gamma-selective inhibitors.
COMPUTERS IN BIOLOGY AND MEDICINE
(2022)
Review
Biotechnology & Applied Microbiology
Ankit Shah, Jacqueline C. Barrientos
Summary: The development of highly effective targeted therapies has revolutionized treatment approaches for CLL/SLL patients. Duvelisib, a first-in-class oral agent with dual inhibitor activity against PI3K delta and gamma isoforms, has shown promising activity in early trials. However, therapy discontinuation due to serious adverse events remains a major concern. Ongoing clinical trials are exploring combination strategies and alternate dosing schedules to improve its efficacy and safety profile.
ONCOTARGETS AND THERAPY
(2021)
Article
Oncology
Jacqueline C. Barrientos, Peter Hillmen, Gilles Salles, Jeff Sharman, Stephan Stilgenbauer, Oksana Gurtovaya, Guan Xing, Bianca Ruzicka, Pankaj Bhargava, Paolo Ghia, John M. Pagel
Summary: Simultaneous anticoagulation and antiplatelet therapy did not increase bleeding risk in patients with B-cell malignancies treated with idelalisib. Hemorrhagic risk is prevalent in these patients.
LEUKEMIA & LYMPHOMA
(2021)
Review
Oncology
Lori A. Leslie
Summary: When choosing therapy for patients with indolent non-Hodgkin lymphoma, factors such as age and comorbid conditions need to be considered. While incurable, iNHL is a chronic disease with a long overall survival period. Despite advancements in available therapies, progress in iNHL has been slow.
CURRENT TREATMENT OPTIONS IN ONCOLOGY
(2021)
Article
Oncology
Giovanni Fuca, Margherita Ambrosini, Luca Agnelli, Silvia Brich, Francesco Sgambelluri, Roberta Mortarini, Serenella M. Pupa, Michele Magni, Liliana Devizzi, Paola Matteucci, Antonello Cabras, Roberta Zappasodi, Francesca De Santis, Andrea Anichini, Filippo De Braud, Alessandro M. Gianni, Massimo Di Nicola
Summary: This study provides a 15-year follow-up of vaccination with tumor-loaded DCs in relapsed iNHL patients, showing long-term benefit without significant toxicity, improved survival rates, and potential for long-lasting complete responses. Biomarker analysis revealed different gene expressions in responder versus non-responder tumors, indicating a potential for personalized treatment approaches. The study suggests that active immunization with DCs may be a promising strategy in relapsed iNHL treatment, warranting further investigation in combination with other novel immunotherapy agents.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Nathan H. Fowler, Felipe Samaniego, Wojciech Jurczak, Nilanjan Ghosh, Enrico Derenzini, James A. Reeves, Wanda Knopinska-Posluszny, Chan Y. Cheah, Tycel Phillips, Ewa Lech-Maranda, Bruce D. Cheson, Paolo F. Caimi, Sebastian Grosicki, Lori A. Leslie, Julio C. Chavez, Gustavo Fonseca, Sunil Babu, Daniel J. Hodson, Spencer H. Shao, John M. Burke, Jeff P. Sharman, Jennie Y. Law, John M. Pagel, Hari P. Miskin, Peter Sportelli, Owen A. O'Connor, Michael S. Weiss, Pier Luigi Zinzani
Summary: Umbralisib demonstrated meaningful clinical activity in heavily pretreated patients with iNHL. The safety profile was manageable, with a relatively low incidence of immune-mediated toxicities and adverse event-related discontinuations.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Chemistry, Medicinal
Kehui Zhang, Lei Huang, Fangfang Lai, Songwen Lin, Hua Tian, Deyu Wu, Xiaoguang Chen, Heng Xu
Summary: Simultaneous inhibition of PI3K and HDAC has been proven to have a synergistic anti-tumor effect, providing rationale for the use of PI3K/HDAC dual inhibitors in cancer treatment. The exceptional effect of PI3K/HDAC dual inhibitors against DLBCL, especially RR-DLBCL, has gained much attention. Our previous research on PI3K/HDAC dual inhibitors based on the 4-methylquinazoine scaffold demonstrated their ability to suppress the growth of solid tumors and hematologic malignancies both in vitro and in vivo, highlighting their potential as novel therapeutic agents for cancer. In this study, we further investigated the anti-tumor activity of one of our compounds against DLBCL cell lines and in vivo zebrafish xenograft model, as well as the underlying mechanism, aiming to provide a new therapeutic agent for treating DLBCL.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
(2022)
Article
Hematology
Andrea Iannello, Nicoletta Vitale, Silvia Coma, Francesca Arruga, Amy Chadburn, Arianna Di Napoli, Carlo Laudanna, John N. Allan, Richard R. Furman, Jonathan A. Pachter, Silvia Deaglio, Tiziana Vaisitti
Summary: This study demonstrates the efficacy of dual targeting of PI3K-delta/gamma and Bcl-2 in Richter syndrome (RS), with combination therapy being more effective than monotherapy. Different RS cells show variable responses to Duv and Ven, but the Duv/Ven combination shows the best tumor growth inhibition.
Article
Oncology
Jennifer A. Foltz, Brian T. Hess, Veronika Bachanova, Nancy L. Bartlett, Melissa M. Berrien-Elliott, Ethan McClain, Michelle Becker-Hapak, Mark Foster, Timothy Schappe, Brad Kahl, Neha Mehta-Shah, Amanda F. Cashen, Nancy D. Marin, Kristen McDaniels, Chaz Moreno, Matthew Mosior, Feng Gao, Obi L. Griffith, Malachi Griffith, Julia A. Wagner, Narendranath Epperla, Amy D. Rock, John Lee, Allegra A. Petti, Patrick Soon-Shiong, Todd A. Fehniger
Summary: The combination therapy of N-803 with rituximab demonstrated safety and durable clinical responses in patients with indolent non-Hodgkin lymphoma, including rituximab-refractory patients. Analysis using CITE-seq revealed altered molecular programs in NK cells and monocytes post-treatment, suggesting the potential for further investigation of N-803 in combination with immunotherapies.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Caron A. Jacobson, Julio C. Chavez, Alison R. Sehgal, Basem M. William, Javier Munoz, Gilles Salles, Pashna N. Munshi, Carla Casulo, David G. Maloney, Sven de Vos, Ran Reshef, Lori A. Leslie, Ibrahim Yakoub-Agha, Olalekan O. Oluwole, Henry Chi Hang Fung, Joseph Rosenblatt, John M. Rossi, Lovely Goyal, Vicki Plaks, Yin Yang, Remus Vezan, Mauro P. Avanzi, Sattva S. Neelapu
Summary: This study assessed the use of axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma and found that it showed high rates of durable responses and had a manageable safety profile.